Noopept, tablets 10 mg 50 pcs

Pharmacotherapeutic group: nootropic agent.

The ATX code: N06BX

Pharmacological properties

Pharmacodynamics

Noopept^® has nootropic and neuroprotective properties. Improves learning ability and memory by acting on all phases of processing: initial information processing, consolidation, retrieval. Prevents the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paroxysmal phase of sleep.

The neuroprotective (protective) effect of Noopept® is manifested by increasing resistance of brain tissue to damaging influences (trauma, hypoxia, electroconvulsive, toxic) and weakening of the degree of damage of brain neurons.

The drug reduces focal volume in a thrombotic model of stroke and prevents neuronal death in tissue culture of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate and free-radical oxygen.

Noopept^® has antioxidant action, blocks potential-dependent calcium channels of neurons, attenuating the neurotoxic effects of excess calcium, improves blood rheological properties with antiaggregant, fibrinolytic, anticoagulant properties.

The nootropic effect of the drug is connected with the formation of cycloprolilglycine which is similar in structure to the endogenous cyclic dipeptide with antiamnestic activity, and also with the presence of choline-positive action.

Noopept^® increases the amplitude of the transcallosal response, facilitating associative connections between cerebral hemispheres at the level of cortical structures. Helps to restore memory and other cognitive functions impaired as a result of damaging influences – brain trauma, local and global ischemia, prenatal damage (alcohol, hypoxia).

The therapeutic effect of the drug in patients with organic disorders of the

the central nervous system is manifested starting from day 5-7 of treatment. At first the anxiolytic and mild stimulant effects available in the activity spectrum of Noopept® are realized, which are manifested by decrease or disappearance of anxiety, increased irritability, affective lability, sleep disturbances. After 14-20 days of therapy a positive effect of the drug on cognitive functions, attention and memory parameters is observed.

Noopept® has a vegetal-normalizing effect, reduces headaches, orthostatic disorders and tachycardia.

There is no withdrawal syndrome on withdrawal of the drug.

The drug does not cause any harmful effect on internal organs; it does not lead to changes in the cellular composition of blood and biochemical parameters of blood and urine; it has no immunotoxic, teratogenic effect and does not show mutagenic properties.

Pharmacokinetics

Omberacetam, absorbed in the gastrointestinal tract, enters the systemic bloodstream unchanged, penetrates through the blood-brain barrier and is determined in the brain in higher concentrations than in blood. Time to reach maximum concentration averages 15 minutes.

Indications

Impaired memory, attention, other cognitive functions and emotionally labile disorders (including in elderly patients) with:

consequences of traumatic brain injury,

post-concussion syndrome,

cerebrovascular insufficiency (encephalopathies of various origins),

asthenic disorders,

other conditions with signs of decreased intellectual productivity.

Pharmacological effect

Pharmacotherapeutic group: nootropic agent.

ATX code: N06ВХ

Pharmacological properties

Pharmacodynamics

Noopept® has nootropic and neuroprotective properties. Improves learning ability and memory, acting on all phases of processing: initial information processing, consolidation, retrieval. Prevents the development of amnesia caused by electric shock, blockade of central cholinergic structures, glutamatergic receptor systems, and deprivation of the paradoxical phase of sleep.

The neuroprotective (protective) effect of Noopept® is manifested in increasing the resistance of brain tissue to damaging influences (trauma, hypoxia, electroconvulsive, toxic) and reducing the degree of damage to brain neurons.

The drug reduces the volume of the lesion in a thrombotic stroke model and prevents the death of neurons in cultured tissue of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate and free radical oxygen.

Noopept® has an antioxidant effect, blocks voltage-dependent calcium channels of neurons, weakening the neurotoxic effect of excess calcium, improves the rheological properties of the blood, having antiplatelet, fibrinolytic, and anticoagulant properties.

The nootropic effect of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to the endogenous cyclic dipeptide, which has antiamnestic activity, as well as the presence of a choline-positive effect.

Noopept® increases the amplitude of the transcallosal response, facilitating associative connections between the cerebral hemispheres at the level of cortical structures. Promotes the restoration of memory and other cognitive functions impaired as a result of damaging influences – brain injury, local and global ischemia, prenatal damage (alcohol, hypoxia).

Therapeutic effect of the drug in patients with organic disorders

central nervous system appears starting from 5-7 days of treatment. Initially, the anxiolytic and mild stimulating effects present in the spectrum of Noopept® activity are realized, manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disturbances. After 14-20 days of therapy, a positive effect of the drug on cognitive functions, parameters of attention and memory is revealed.

Noopept® has a vegetative-normalizing effect, helps reduce headaches, orthostatic disorders, and tachycardia.

When discontinuing the drug, no withdrawal syndrome is observed.

Does not have a damaging effect on internal organs; does not lead to changes in the cellular composition of the blood and biochemical parameters of blood and urine; does not have immunotoxic, teratogenic effects, does not exhibit mutagenic properties.

Pharmacokinetics

Omberacetam, being absorbed in the gastrointestinal tract, enters the systemic circulation unchanged, penetrates the blood-brain barrier, and is detected in the brain in higher concentrations than in the blood. The time to reach maximum concentration is on average 15 minutes.

The half-life from blood plasma is 0.38 hours. Partially remains unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has high relative bioavailability (99.7%), does not accumulate in the body, and does not cause drug dependence.

Special instructions

If it is necessary to increase the dose of the drug (up to 30 mg/day), with long-term use, as well as with simultaneous use with other drugs, the occurrence of adverse reactions or worsening of the condition, you should consult a doctor.

Impact on the ability to drive vehicles and machinery

Noopept® does not affect the ability to operate machinery and vehicles.

Active ingredient

Omberacetam

Composition

Active ingredient:

Omberacetam (noopept) – 10.0 mg;

excipients:

lactose monohydrate – 55.0 mg,

potato starch – 13.5 mg,

microcrystalline cellulose 101 – 21.2 mg,

magnesium stearate – 0.3 mg,

povidone (polyvinyl-pyrrolidone, povidone K-25) – 0.0008 mg.

Pregnancy

The drug is contraindicated for use during pregnancy.

If necessary
use of the drug during breastfeeding, it is necessary to resolve the issue of
stopping breastfeeding.

Contraindications

Pregnancy, breastfeeding period. Age up to 18 years. Hypersensitivity to the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Severe dysfunction of the liver and kidneys.

Side Effects

Allergic reactions are possible.

In patients with arterial hypertension, mostly severe, while taking the drug, a rise in blood pressure may be observed.

Interaction

No interaction of Noopept® with alcohol has been established,
sleeping pills and antihypertensive drugs and psychostimulant drugs
actions.

Overdose

Specific manifestations of overdose have not been established.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Pharmstandard-Leksredstva, Russia